ClinicalTrials.gg
CompletedNCT07678892periimpl10yUpdated Jul 2, 2026

10 Year Follow-up on Reconstructive Bone Procedures for Peri-implantitis

An observational study in Peri-Implantitis, sponsored by Kristianstad University. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Kristianstad University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Peri-Implantitis with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Sweden.

Started
2000
the only one that year
Observational
9 of 21
3 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Kristianstad University

Among the 21 studies in Peri-Implantitis with a site in Sweden, this one is the only one that started in 2000, is one of 9 observational ones, and was the 21st registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

5 of the 21 studies in Peri-Implantitis with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peri-Implantitis with a site in Sweden, or all of them as a file.
02

Study summary

The purpose of this 10 year observational follow-up study was to evaluate the long-term outcomes of reconstructive surgical treatment of peri-implantitis. Two treatment approaches have been compared using a bone substitute with or without a resorbable membrane.The objective was to assess their effectiveness and determine wheter one treatment strategy provided superior long-term outcomes.

Participants were invited for clinical and radiographic examinations of the previously treated implant. Clinical assessments included probing pocket depth measurements, evaluation of bleeding on probing, presence of suppuration, and radiographic assessment of peri-implant bone levels.

Read the detailed description

The objective of this 10-year observational follow-up study was to investigate the long-term clinical and radiographic outcomes of reconstructive surgical treatment and to evaluate potential differences between two reconstructive treatment protocols.

The study population consisted of patients previously treated for per-implantitis using one of the following approaches.

Group 1: Surgical treatment using a bone substitute material (Algipor) combined with a barrier membrane (Osseoquest)

Group 2: Surgical treatment using a bone substitute materail alone (Algipor)

At the time of treatment, all patients received systemic antibiotic therapy consisting of Amoxicillin 375 mg three times daily and Metronidazole 400 mg twice daily for 10 days, initiated one day before surgery.

The study aimed to provide further knowledge regarding the long-term effectiveness and stability of reconstructive peri-implantitis treatment and to investigate potential differences between the two treatment modalities.

Following surgery all patients participated in a structured supportive maintanance program with supportive periodontal therapy every third month and annual clinical evaluations.

At the 10 year follow-up examination, the implant(s) was assessed clinically and radiographically. Clinical parameters included probing pocket depht, bleeding on probing, suppuration, plaque accumulation and implant survival. Probing measurements were performed using a standardized probing force of 0.25 N with a calibrated periodontal probe.

Bleeding scores were recorded at four sites per implant using the following scale:

0=no bleeding

  1. bleeding point
  2. bleeding line
  3. drop of blood

Plaque accumulation was recorded as present or absent, following plaque disclosure.

To minimize examiner variability, all clinical examinations was performed by the same periodontist.

The primary outcome measures were radiographic bone fill and changes in probing pocket depth at treated implant sites. Secondary outcome measures included bleeding on probing, suppuration, plaque scores, and implant survival.

Statistical analyses were performed using parametric or non-parametric methods depending on data distribution. Statistical significance was defined as p\< 0.05.

Patients received both oral and written information regarding the study and provided written informed consent prior to participation. Participation was voluntary and the participants could withdraw from the study at any time without consequences. The study had received approval from the appropiate ethical reiew authority.

03

Conditions studied

  • Peri-Implantitis

Browse trials for

Keywords

  • peri.implantitis
  • reconstructive surgery
  • long time follo-up
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with at least one dental implant with peri-implantitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An implant demonstrating a progressive bone loss of ≥ 3 threads ( ≥ 1,8 mm) following the first year of healing
  • A vertical component needed to be present at the surgical intervention in order to justify the use of a bone augmentation procedure
  • Bleeding on probing and/or suppuration should also be present

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1

    Bone reconstructive surgery with a bone graft material (Algipor) and a resorbable membrane (Osseoquest)

    Procedure: Treatment with a bone graft and a membrane

  • Group 2

    Bone reconstructive surgery with a bone graft material (Algipor)

    Procedure: Treatment with a bone graft

Interventions

  • ProcedureTreatment with a bone graft and a membrane

    Dental implants with a diagnosis of peri-implantitis treated with reconstructive surgery and a bone graft and a membrane

  • ProcedureTreatment with a bone graft

    Dental, implants with a diagnosis of peri.implantitis treated with reconstructive surgery and a bone graft alone

06

What researchers measure

Primary outcomes

  1. Bone fill

    Radographic bone fill measured mesial and distal in mm and percent at the implant on an intra-oral radiograph. Measurements will be performed by a blinded radiologist in mm and percent

    Time frame: 10 years after surgical reconstrucyive bone procedures

Secondary outcomes

  1. Probing pocket depths changes

    Changes in probing pocket depths at the implant measured at four sites in mm

    Time frame: 10 years after surgical reconstructive bone procedures

Other outcomes

  1. Bleeding

    Bleeding on probing measured at the implant at four sites as present or absent

    Time frame: 10 years after surgical reconstructive bone procedures

  2. Graded bleeding

    Graded bleeding measured at the implant at four sites as: 0=no bleeding 1= point of bleeding 2=line of bleeding and 3=drop of bleeding

    Time frame: 10 years after surgical reconstructive bone procedures

07

Study locations

1 site
  • Kristianstad University
    Kristianstad, Kristianstad 29198, Sweden
08

References and documents

Publications

  • Roos-Jansaker AM, Persson GR, Lindahl C, Renvert S. Surgical treatment of peri-implantitis using a bone substitute with or without a resorbable membrane: a 5-year follow-up. J Clin Periodontol. 2014 Nov;41(11):1108-14. doi: 10.1111/jcpe.12308. Epub 2014 Oct 17. PubMed 25195613 ↗
  • Roos-Jansaker AM, Lindahl C, Persson GR, Renvert S. Long-term stability of surgical bone regenerative procedures of peri-implantitis lesions in a prospective case-control study over 3 years. J Clin Periodontol. 2011 Jun;38(6):590-7. doi: 10.1111/j.1600-051X.2011.01729.x. Epub 2011 Apr 13. PubMed 21488935 ↗
  • Roos-Jansaker AM, Renvert H, Lindahl C, Renvert S. Surgical treatment of peri-implantitis using a bone substitute with or without a resorbable membrane: a prospective cohort study. J Clin Periodontol. 2007 Jul;34(7):625-32. doi: 10.1111/j.1600-051X.2007.01102.x. PubMed 17555414 ↗

Individual participant data

Plan to share: Undecided — May be shared upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2000 to primary completion in Jan 2013, 154 months.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's 154 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartActual
Mar 1, 2000
Primary completionActual
Jan 1, 2013
CompletionActual
Jan 1, 2013
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07678892
Lead sponsor
Kristianstad University
Responsible party
Viveca Wallin Bengtsson (Principal Investigator, Kristianstad University) — Principal investigator
First posted
Jul 1, 2026
Start date
Mar 1, 2000
Primary completion
Jan 1, 2013
Completion
Jan 1, 2013
Last update
Jul 2, 2026

Study contacts

Ann-Marie R Jansåker
study director · Malmö University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion